Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer

Bernard Fisher, James J. Dignam, Birol Emir, +10

JNCI Journal of the National Cancer Institute

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.

Bernard Fisher, Stewart Anderson, D. Lawrence Wickerham, +16

Journal of Clinical Oncology

Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.

Bernard Fisher, James J. Dignam, Eleftherios P. Mamounas, +12

Journal of Clinical Oncology

Amelioration of vincristine neurotoxicity by glutamic acid

Don V. Jackson, H. Bradley Wells, J. N. Atkins, +5

The American Journal of Medicine

Glutamic AcidMedicineNeuroprotectionNeurosciencePharmacology

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

Norman Wolmark, Greg Yothers, M J O'Connell, +6

Journal of Clinical Oncology

Bevacizumab AdministrationGastrointestinal OncologyMedicineMetronomic TherapyPharmacology +13

Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group

C.S. Cleeland, Russell K. Portenoy, Montserrat Rué, +7

Annals of Oncology

Pain TherapyPain ResearchOncologyHealth SciencesPain Medicine +10

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

Jonathan E. Rosenberg, Susan Halabi, Ben L. Sanford, +6

Annals of Oncology

UrologyCalgb 90207Genitourinary CancerMedicinePhase Ii Study +4

A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342

Roy S. Herbst, Kari Chansky, Karen Kelly, +7

Journal of Clinical Oncology

Cancer PharmacologyPathologyOncologyPhase IiMetronomic Therapy +18

Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study

Julie R. Brahmer, Ramaswamy Govindan, Silvia Novello, +7

Journal of Clinical Oncology

Neuro-oncologySunitinib MalateMedicineCancer ManagementMetronomic Therapy +13

Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902

Caio Rocha‐Lima, James E. Herndon, Mi-Ji Lee, +4

Annals of Oncology

Phase Ii TrialMedicineMetronomic TherapyPharmacologyPharmacotherapy +4